Routine CT lung cancer screening of high-risk individuals would save thousands of lives per year for less than a dollar a month per patient if it were implemented throughout the U.S. and would be even cheaper than breast screening.
Small dosage CT screening for lung cancer carried out safely, proficiently and rightfully has become a popular procedure for those diagnosed with Lung Cancer. Drawing knowledge from other screening histories, and from the recent support of the effectiveness of CT screening in a high risk population, it is clear that achieving this goal will require a well-informed public and the commitment of medical professionals to institute best practices. Advances in imaging and biomedical research will continue to evolve rapidly. The breach of CT screening into the healthcare system presents a unique opportunity to develop a coexisting mechanism for collecting data and specimens to accelerate that research and for introducing refinements into the screening process as imaging and biomedical advances occur and is validated.
Given the increasing number of hospitals who study lung cancer, this conference has been developed to provide a forum to all physicians and educators. This multidisciplinary meeting will promote interaction between Medical Oncologists, Radiation Oncologists and Principle Investigators to achieve the best possible outcome for thoracic cancer patients.
Founded in 1896 by a group of local physicians and concerned citizens, Winthrop-University Hospital is Long Island’s first voluntary and second largest hospital. The university-affiliated medical center offers sophisticated diagnostic and therapeutic care in virtually every specialty and sub-specialty of medicine and surgery. Winthrop’s new 95,000 square-foot, state-of-the-art Research and Academic Center is a five-story building which was designed specifically to foster the intersection of Winthrop’s science and academic missions and encourage collaboration among researchers and clinicians. Winthrop boasts several specialized Centers that are dedicated to Cancer Care, Digestive Disorders, Family Care including Women’s and Children’s Health Services, Lung Care and Neurosciences. Our Cancer Care Program is the only QOPI certified program on Long Island. Winthrop’s Lung Cancer Screening Program was started in 2012 as part of our multidisciplinary Lung Cancer Program. The program is certified by both Lung Cancer Alliance and American College of Radiology. The screening program is coordinated by an oncology certified registered nurse who follows each case to completion.
Senior-level executives representing Hospitals, Health Systems, Physician Clinics and Hospital Management Groups:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.
Invivo’s a business of Royal Philips and has nearly over a 20‐year history as a pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI‐compatible interventional devices. Invivo’s committed to providing technology solutions to keep pace with the needs of a growing healthcare market. Focusing on a better way for you and your patients, Invivo offers products & services for successful implementation of a comprehensive CT lung screening program throughout the continuum of patient care.
Myriad myPlan® Lung Cancer is a molecular prognostic test that measures the expression of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in patients with early-stage non-small cell lung adenocarcinoma. Current medical society guidelines rely on cancer stage and subjective high risk features to determine lung cancer treatment. Two patients with the same lung cancer stage may have very different estimates of mortality risk when tumor aggressiveness is taken into account. MyPlan® Lung Cancer prognostic score combines molecular information with cancer stage to better predict the five-year risk of lung cancer specific death than score alone. Gaining insight into tumor aggressiveness will also help determine if surgery alone is sufficient, or if a more aggressive treatment is needed.
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest patient-founded, patient-focused and patient-driven philanthropies devoted to eradicating lung cancer through research, early detection, education and treatment. The Foundation’s goal is to work with a diverse group of healthcare providers, researchers donors, patients and caregivers to identify solutions and turn lung cancer into a chronically managed disease by 2023.